Azopharma Product Development Group, Inc. plans to implement Xcelodose technology at ApiCross Drug Delivery Technologies, its formulations development facility. Xcelodose technology is a powder micro-dosing system developed by Meridica that offers a powder dispensing system for small-scale capsule filling. Xcelodose Technology assists in conserving research material as well as reducing various preformulation activities.
The technology provides precision filling with low weights and minimal waste, eliminating the need for blending. Other benefits include: minimizing or eliminating the need for early formulation development and associated reduction of stability testing, reducing amount of API needed to get to first-in-human studies and reducing analytical development costs during early phase development.
According to Phil Meeks, Azopharma's chief executive officer, “Xcelodose technology allows us to more precisely prepare doses of clinical trial material. This enables our clients to stretch out valuable research material which is often costly and time consuming to make."
He added, “Many of our clients are small or virtual companies that are trying to minimize their financial burn rate. If we can save them a trip to the synthesis lab or reduce their time in Preformulation, we’ve gone a long way in stretching their resources.”
Magazine
